The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity

The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity

Chimeric antigen receptors (CARs) are effective tools for directing T cell killing of tumors, but may cause adverse side effects. Here the authors show that coupling of antigen-recognition and CD3-binding in a modular format induces more efficient anti-tumour responses but reduced toxicity when comp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christopher W. Helsen, Joanne A. Hammill, Vivian W. C. Lau, Kenneth A. Mwawasi, Arya Afsahi, Ksenia Bezverbnaya, Lisa Newhook, Danielle L. Hayes, Craig Aarts, Bojana Bojovic, Galina F. Denisova, Jacek M. Kwiecien, Ian Brain, Heather Derocher, Katy Milne, Brad H. Nelson, Jonathan L. Bramson
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/e6ef202d9e6344acbce6ee90ed3c483d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Chimeric antigen receptors (CARs) are effective tools for directing T cell killing of tumors, but may cause adverse side effects. Here the authors show that coupling of antigen-recognition and CD3-binding in a modular format induces more efficient anti-tumour responses but reduced toxicity when compared with current CARs.

Ejemplares similares